SCHEMBL4162865

SCHEMBL4162865

Cc1ccc(NC(=O)c2ccnc3[nH]c(-c4cccnc4)nc23)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.56
PIK3CA P42336 2/20 0.47
MTOR P42345 2/20 0.47
ALDH1A1 P00352 4/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 2/20 0.46
TP53 P04637 2/20 0.46
RECQL P46063 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PKN1 Q16512 1/20 0.44
PKN2 Q16513 1/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
NAMPT P43490 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2C9 P11712 1/20 0.43
GFER P55789 1/20 0.43
ABL1 P00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4164597 0.90 GSK3B (0.59) GSK3BPIK3CAMTORALDH1A1HPGD
SCHEMBL4147510 0.88 GSK3B (0.50) GSK3BALDH1A1HPGDHSD17B10POLB
SCHEMBL4152791 0.87 GSK3B (0.73) GSK3BPIK3CAMTORALDH1A1L3MBTL1
SCHEMBL4152883 0.87 GSK3B (0.52) GSK3BPIK3CAMTORPOLBTP53
SCHEMBL4169206 0.87 GSK3B (0.59) GSK3BPIK3CAMTORLMNA
SCHEMBL4149991 0.86 GSK3B (0.60) GSK3BPIK3CAMTORL3MBTL1NAMPT
SCHEMBL13778234 0.85 GSK3B (0.55) GSK3BPIK3CAMTORALDH1A1HSD17B10
SCHEMBL4159232 0.85 GSK3B (0.59) GSK3BPIK3CAMTORNAMPT
SCHEMBL4162649 0.85 GSK3B (0.58) GSK3BPIK3CAMTORALDH1A1POLB
SCHEMBL4160365 0.84 GSK3B (0.50) GSK3BPIK3CAMTORALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885PIK3CA 64/4885MTOR 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.